{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T10:44:55Z","timestamp":1775040295810,"version":"3.50.1"},"reference-count":197,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epigenomes"],"abstract":"<jats:p>Epithelial ovarian carcinoma (EOC) is the most common type of ovarian cancer and represents the most lethal gynecologic neoplasm. EOC is usually diagnosed at late stages due to its nonspecific signs and symptoms. Although significant clinical advances have been made in other types of malignancies, EOC remains a disease that requires further biological research to identify new therapeutic targets or new treatment alternatives, as conventional approaches are often ineffective or lead to the development of resistance and unwanted side effects. There are a significant number of natural products from which commercially available drugs have been derived, largely for the treatment of cancer, but none of them focus on epigenetic changes in specific targets in EOC. Based on the above, this work focuses on describing the in vitro and in vivo findings from the last twelve years derived from the action of important phytochemicals on epigenetic targets in ovarian cancer, among other mechanisms of action, revealing that there is a significant gap to be bridged in terms of the transition from basic to applied research regarding the potential of plant-derived molecules as possible epidrugs in EOC.<\/jats:p>","DOI":"10.3390\/epigenomes10020023","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T08:08:34Z","timestamp":1775030914000},"page":"23","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Natural Compounds as Epimodulators in Epithelial Ovarian Cancer"],"prefix":"10.3390","volume":"10","author":[{"given":"M\u00e9lida del Rosario","family":"Lizarazo-Taborda","sequence":"first","affiliation":[{"name":"Laboratorio de Investigaci\u00f3n en C\u00e1ncer e Infecciones (LICI), Departamento de Microbiolog\u00eda y Patolog\u00eda, CUCS, UDG, Guadalajara 44340, Jalisco, Mexico"},{"name":"Doctorado en Microbiolog\u00eda M\u00e9dica, Departamento de Microbiolog\u00eda y Patolog\u00eda, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0015-9444","authenticated-orcid":false,"given":"Julio C\u00e9sar","family":"Villegas-Pineda","sequence":"additional","affiliation":[{"name":"Laboratorio de Investigaci\u00f3n en C\u00e1ncer e Infecciones (LICI), Departamento de Microbiolog\u00eda y Patolog\u00eda, CUCS, UDG, Guadalajara 44340, Jalisco, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2308-656X","authenticated-orcid":false,"given":"Holver","family":"Parada","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias M\u00e9dicas y de la Salud, Instituto de Investigaci\u00f3n Masira, Universidad de Santander, C\u00facuta 540003, Norte de Santander, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Galvis","sequence":"additional","affiliation":[{"name":"Grupo de Investigaci\u00f3n Majumba, Facultad de Ciencias B\u00e1sicas, Universidad Francisco de Paula Santander, C\u00facuta 540003, Norte de Santander, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4786-3431","authenticated-orcid":false,"given":"Javier","family":"Soto","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias M\u00e9dicas y de la Salud, Instituto de Investigaci\u00f3n Masira, Universidad de Santander, C\u00facuta 540003, Norte de Santander, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network (2011). Integrated genomic analyses of ovarian carcinoma. Nature, 474, 609\u2013615.","DOI":"10.1038\/nature10166"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.21037\/gs-20-325","article-title":"Secondary and tertiary ovarian cancer recurrence: What is the best management?","volume":"9","author":"Garzon","year":"2020","journal-title":"Gland. Surg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/onc.2011.384","article-title":"Molecular mechanisms of cisplatin resistance","volume":"31","author":"Galluzzi","year":"2012","journal-title":"Oncogene"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/bies.20087","article-title":"The somatic mutation theory of cancer: Growing problems with the paradigm?","volume":"26","author":"Soto","year":"2004","journal-title":"Bioessays"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Nguyen, H.T., Tian, G., and Murph, M.M. (2014). Molecular epigenetics in the management of ovarian cancer: Are we investigating a rational clinical promise?. Front. Oncol., 4.","DOI":"10.3389\/fonc.2014.00071"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/clpt.2012.152","article-title":"Epigenomics and interindividual differences in drug response","volume":"92","author":"Ivanov","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1158\/0008-5472.CAN-04-2438","article-title":"Circulating tumor-specific DNA: A marker for monitoring efficacy of adjuvant therapy in cancer patients","volume":"65","author":"Fiegl","year":"2005","journal-title":"Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"NEJM"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1001\/jamaoncol.2018.1977","article-title":"Association of MGMT promoter methylation status with survival outcomes in patients with high-risk glioma treated with radiotherapy and temozolomide: An analysis from the NRG oncology\/RTOG 0424 trial","volume":"4","author":"Bell","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s00432-014-1704-5","article-title":"BRCA1 promoter methylation is a marker of better response to platinum\u2013taxane-based therapy in sporadic epithelial ovarian cancer","volume":"140","author":"Ignatov","year":"2014","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13148-025-01917-w","article-title":"BRCA1 promoter methylation predicts PARPi response in ovarian cancer: Insights from the KOMET study","volume":"17","author":"Nougarede","year":"2025","journal-title":"Clin. Epigenetics"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13148-021-01149-8","article-title":"Transcriptional epigenetic regulation of Fkbp1\/Pax9 genes is associated with impaired sensitivity to platinum treatment in ovarian cancer","volume":"13","author":"Soto","year":"2021","journal-title":"Clin. Epigenetics"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1021\/np960037q","article-title":"Five novel mono-tetrahydrofuran ring acetogenins from the seeds of Annona muricata","volume":"59","author":"Rieser","year":"1996","journal-title":"J. Nat. Prod."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Habli, Z., Toumieh, G., Fatfat, M., Rahal, O.N., and Gali-Muhtasib, H. (2017). Emerging cytotoxic alkaloids in the battle against cancer: Overview of molecular mechanisms. Molecules, 22.","DOI":"10.3390\/molecules22020250"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1111\/bph.70014","article-title":"Natural products and cancer: From drug discovery to prevention and therapy","volume":"182","author":"Izzo","year":"2025","journal-title":"Br. J. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"114145","DOI":"10.1016\/j.biopha.2022.114145","article-title":"Podophyllotoxin and its derivatives: Potential anticancer agents of natural origin in cancer chemotherapy","volume":"158","author":"Motyka","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1021\/acs.jnatprod.7b01012","article-title":"Quest for efficacious next-generation taxoid anticancer agents and their tumor-targeted delivery","volume":"81","author":"Ojima","year":"2018","journal-title":"J. Nat. Prod."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"408","DOI":"10.37349\/eds.2024.00054","article-title":"Natural products as anticancer agents and enhancing their efficacy by a mechanism-based precision approach","volume":"2","author":"Safe","year":"2024","journal-title":"Explor. Drug Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1021\/acs.jnatprod.9b01285","article-title":"Natural products as sources of new drugs over the nearly four decades from 01\/1981 to 09\/2019","volume":"83","author":"Newman","year":"2020","journal-title":"J. Nat. Prod."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.fct.2018.11.041","article-title":"Adverse drug reactions of anticancer drugs derived from natural sources","volume":"123","author":"Tewari","year":"2019","journal-title":"Food Chem. Toxicol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000443404","article-title":"Natural products as a vital source for the discovery of cancer chemotherapeutic and chemopreventive agents","volume":"25","author":"Cragg","year":"2016","journal-title":"Med. Princ. Pract."},{"key":"ref_23","first-page":"11","article-title":"The combinatorial chemistry of nature","volume":"384","author":"Verdine","year":"1996","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1751-7915.2010.00221.x","article-title":"Natural products for cancer chemotherapy","volume":"4","author":"Demain","year":"2011","journal-title":"Microb. Biotechnol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2217\/epi.09.33","article-title":"DNA hypomethylation in cancer cells","volume":"1","author":"Ehrlich","year":"2009","journal-title":"Epigenomics"},{"key":"ref_27","first-page":"1449","article-title":"A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinum-based chemotherapy in epithelial ovarian cancer","volume":"27","author":"Watanabe","year":"2007","journal-title":"Anticancer. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1158\/0008-5472.CAN-11-3909","article-title":"Epigenetic resensitization to platinum in ovarian cancer","volume":"72","author":"Matei","year":"2012","journal-title":"Cancer Res."},{"key":"ref_29","first-page":"5329","article-title":"BRCA1 promoter region hypermethylation in ovarian carcinoma: A population-based study","volume":"60","author":"Baldwin","year":"2000","journal-title":"Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.molonc.2012.12.007","article-title":"BRCA1\/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation","volume":"7","author":"Stordal","year":"2013","journal-title":"Mol. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.4238\/2015.May.4.11","article-title":"Cumulative methylation alternations of gene promoters and protein markers for diagnosis of epithelial ovarian cancer","volume":"14","author":"Xing","year":"2015","journal-title":"Genet. Mol. Res. GMR"},{"key":"ref_32","first-page":"609","article-title":"Opioid-binding protein\/cell adhesion molecule-like (OPCML) gene and promoter methylation status in women with ovarian cancer","volume":"27","author":"Czekierdowski","year":"2006","journal-title":"Neuro Endocrinol. Lett."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/ng1183","article-title":"OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer","volume":"34","author":"Sellar","year":"2003","journal-title":"Nat. Genet."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.1038\/sj.onc.1210300","article-title":"Epigenetic silencing of HSulf-1 in ovarian cancer: Implications in chemoresistance","volume":"26","author":"Staub","year":"2007","journal-title":"Oncogene"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"294","DOI":"10.5507\/bp.2013.079","article-title":"Importance of promoter methylation of GATA4 gene in epithelial ovarian cancer","volume":"157","author":"Chmelarova","year":"2013","journal-title":"Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc Czechoslov."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.3892\/etm.2012.715","article-title":"Methylation of tumor suppressor genes in ovarian cancer","volume":"4","author":"Ozdemir","year":"2012","journal-title":"Exp. Ther. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1476-4598-6-45","article-title":"DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets","volume":"6","author":"Wu","year":"2007","journal-title":"Mol. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/ijgc-00009577-200602001-00031","article-title":"Methylation of death-associated protein kinase in ovarian carcinomas","volume":"16","author":"Collins","year":"2006","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"6476","DOI":"10.1158\/0008-5472.CAN-04-1529","article-title":"Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients","volume":"64","author":"Battagli","year":"2004","journal-title":"Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/jnci\/92.7.564","article-title":"Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors","volume":"92","author":"Esteller","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/cncr.21992","article-title":"Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential","volume":"107","author":"Wiley","year":"2006","journal-title":"Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Yang, H.J., Liu, V.W., Wang, Y., Tsang, P.C., and Ngan, H.Y. (2006). Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC Cancer, 6.","DOI":"10.1186\/1471-2407-6-212"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/sj.onc.1204175","article-title":"Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours","volume":"20","author":"Agathanggelou","year":"2001","journal-title":"Oncogene"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"8961","DOI":"10.1158\/0008-5472.CAN-05-1187","article-title":"CpG island methylation of DNA damage response genes in advanced ovarian cancer","volume":"65","author":"Teodoridis","year":"2005","journal-title":"Cancer Res."},{"key":"ref_45","first-page":"33","article-title":"RASSF1 and PTEN promoter hypermethylation influences the outcome in epithelial ovarian cancer","volume":"7","author":"Zuberi","year":"2014","journal-title":"Clin. Ovarian Other Gynecol. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/ijgc-00009577-200601000-00034","article-title":"Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer","volume":"16","author":"Wiley","year":"2006","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.1158\/1078-0432.CCR-04-2455","article-title":"Promoter hypermethylation profile of ovarian epithelial neoplasms","volume":"11","author":"Makarla","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nm852","article-title":"Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors","volume":"9","author":"Taniguchi","year":"2003","journal-title":"Nat. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4161\/cbt.5.3.2380","article-title":"Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway","volume":"5","author":"Wang","year":"2006","journal-title":"Cancer Biol. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0002-9440(10)64059-X","article-title":"Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes","volume":"158","author":"Strathdee","year":"2001","journal-title":"Am. J. Pathol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00432-006-0178-5","article-title":"Methylation profile in benign, borderline and malignant ovarian tumors","volume":"133","author":"Tam","year":"2007","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1515\/cclm-2013-0736","article-title":"Methylation of OPCML promoter in ovarian cancer tissues predicts poor patient survival","volume":"52","author":"Zhou","year":"2014","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s10495-013-0923-6","article-title":"The functions and regulations of DAPK in cancer metastasis","volume":"19","author":"Chen","year":"2014","journal-title":"Apoptosis Int. J. Program. Cell Death"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"Luck","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1038\/sj.onc.1209145","article-title":"Quantitative analysis of associations between DNA hypermethylation, hypomethylation, and DNMT RNA levels in ovarian tumors","volume":"25","author":"Ehrlich","year":"2006","journal-title":"Oncogene"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000086183","article-title":"Mechanisms of drug resistance in cancer chemotherapy","volume":"14","author":"Luqmani","year":"2005","journal-title":"Med. Princ. Pract."},{"key":"ref_57","first-page":"6039","article-title":"Reversal of drug resistance in human tumor xenografts by 2\u2019-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter","volume":"60","author":"Plumb","year":"2000","journal-title":"Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Karim, M.F., and Kabir, Y. (2023). Role of histone modifications in the progression of cancer. Handbook of Cancer and Immunology, Springer.","DOI":"10.1007\/978-3-030-80962-1_50-1"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1172\/JCI57349","article-title":"G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer","volume":"122","author":"Dong","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/sj.onc.1209763","article-title":"5-Aza-2\u2032-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation","volume":"26","author":"Wozniak","year":"2007","journal-title":"Oncogene"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/1476-4598-13-189","article-title":"The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis","volume":"13","author":"Hua","year":"2014","journal-title":"Mol. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13148-019-0758-2","article-title":"Histone methyltransferases EHMT1 and EHMT2 (GLP\/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma","volume":"11","author":"Watson","year":"2019","journal-title":"Clin. Epigenetics"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ncb3582","article-title":"ARID1A-mutated ovarian cancers depend on HDAC6 activity","volume":"19","author":"Bitler","year":"2017","journal-title":"Nat. Cell Biol."},{"key":"ref_64","first-page":"1396","article-title":"Knockdown of long non-coding RNA HOTAIR increases cisplatin sensitivity in ovarian cancer by inhibiting cisplatin-induced autophagy","volume":"23","author":"Yu","year":"2018","journal-title":"J. Buon"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ygyno.2014.03.556","article-title":"Overexpression of long non-coding RNA HOTAIR predicts poor patient prognosis and promotes tumor metastasis in epithelial ovarian cancer","volume":"134","author":"Qiu","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1134\/S1022795424700029","article-title":"Hypermethylation in ovarian cancer of long noncoding RNA genes: HOTAIR, GAS5, LINC00472, LINC00886, TUG1","volume":"60","author":"Burdennyy","year":"2024","journal-title":"Russ. J. Genet."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1038\/leu.2017.116","article-title":"Dysfunction of the WT1-MEG3 signaling promotes AML leukemogenesis via p53-dependent and-independent pathways","volume":"31","author":"Lyu","year":"2017","journal-title":"Leukemia"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3892\/or.2014.3208","article-title":"Promoter hypermethylation influences the suppressive role of maternally expressed 3, a long non-coding RNA, in the development of epithelial ovarian cancer","volume":"32","author":"Sheng","year":"2014","journal-title":"Oncol. Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1038\/onc.2017.14","article-title":"LncRNA MEG3 downregulation mediated by DNMT3b contributes to nickel malignant transformation of human bronchial epithelial cells via modulating PHLPP1 transcription and HIF-1\u03b1 translation","volume":"36","author":"Zhou","year":"2017","journal-title":"Oncogene"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"8699","DOI":"10.1158\/0008-5472.CAN-07-1936","article-title":"MicroRNA signatures in human ovarian cancer","volume":"67","author":"Iorio","year":"2007","journal-title":"Cancer Res."},{"key":"ref_71","first-page":"77","article-title":"Radiomics and radiogenomics: Extracting more information from medical images for the diagnosis and prognostic prediction of ovarian cancer","volume":"11","author":"Zeng","year":"2024","journal-title":"Mil. Med. Res."},{"key":"ref_72","first-page":"280","article-title":"Epithelial ovarian cancer: Evolution of management in the era of precision medicine","volume":"69","author":"Lheureux","year":"2019","journal-title":"CA A Cancer J. Clin."},{"key":"ref_73","first-page":"e51011","article-title":"Comparison of the efficacy of cisplatin\/paclitaxel versus carboplatin\/paclitaxel in improving survival and quality of life in the advanced ovarian cancer patient population: A systematic review and meta-analysis of randomized control trials","volume":"15","author":"Mansoor","year":"2023","journal-title":"Cureus"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e70012","DOI":"10.1002\/ctm2.70012","article-title":"Ecological and evolutionary dynamics to design and improve ovarian cancer treatment","volume":"14","author":"Han","year":"2024","journal-title":"Clin. Transl. Med."},{"key":"ref_75","first-page":"a038232","article-title":"Ovarian Cancer Therapy","volume":"15","author":"Miao","year":"2025","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00280-017-3501-8","article-title":"Advances in ovarian cancer therapy","volume":"81","author":"Cortez","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Coleridge, S.L., Bryant, A., Kehoe, S., and Morrison, J. (2021). Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD005343.pub5"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"101627","DOI":"10.1016\/j.ijgc.2024.101627","article-title":"Impact of enhanced recovery after surgery (ERAS) programs in the return to adjuvant chemotherapy in patients with advanced ovarian cancer","volume":"35","author":"Acosta","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Salas Bol\u00edvar, P., Gonzalez-Benitez, C., Carbonell L\u00f3pez, M., D\u00edez Sebastian, J., Hern\u00e1ndez Guti\u00e9rrez, A., and Zapardiel, I. (2025). Prognostic Factors After the First Recurrence of Ovarian Cancer. J. Clin. Med., 14.","DOI":"10.3390\/jcm14020470"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.7150\/ijbs.88539","article-title":"NK-92MI cells engineered with anti-claudin-6 chimeric antigen receptors in immunotherapy for ovarian cancer","volume":"20","author":"Li","year":"2024","journal-title":"Int. J. Biol. Sci."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"van Amerongen, R.A., Tuit, S., Wouters, A.K., van de Meent, M., Siekman, S.L., Meeuwsen, M.H., Wachsmann, T.L., Remst, D.F., Hagedoorn, R.S., and van der Steen, D.M. (2023). PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1121973"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1016\/j.ymthe.2024.06.029","article-title":"Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokine","volume":"32","author":"Basnet","year":"2024","journal-title":"Mol. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/s41586-024-08071-y","article-title":"Transgelin 2 guards T cell lipid metabolism and antitumour function","volume":"635","author":"Hwang","year":"2024","journal-title":"Nature"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/cas.16085","article-title":"Inhibition of palmitoyltransferase ZDHHC12 sensitizes ovarian cancer cells to cisplatin through ROS-mediated mechanisms","volume":"115","author":"Zhang","year":"2024","journal-title":"Cancer Sci."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41419-023-06301-1","article-title":"Inhibition of SF3B1 improves the immune microenvironment through pyroptosis and synergizes with \u03b1PDL1 in ovarian cancer","volume":"14","author":"Wang","year":"2023","journal-title":"Cell Death Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.nano.2016.11.010","article-title":"Nanoparticle delivery of siRNA against TWIST to reduce drug resistance and tumor growth in ovarian cancer models","volume":"13","author":"Roberts","year":"2017","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/s42003-022-03966-w","article-title":"A magnetic antibody-conjugated nano-system for selective delivery of Ca (OH) 2 and taxotere in ovarian cancer cells","volume":"5","author":"Zolfaghari","year":"2022","journal-title":"Commun. Biol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12951-022-01264-5","article-title":"Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 conspicuously overcomes chemoresistant ovarian cancer","volume":"20","author":"Li","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13148-015-0157-2","article-title":"Epigenetic treatment of solid tumours: A review of clinical trials","volume":"7","author":"Nervi","year":"2015","journal-title":"Clin. Epigenetics"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Siebenk\u00e4s, C., Chiappinelli, K.B., Guzzetta, A.A., Sharma, A., Jeschke, J., Vatapalli, R., Baylin, S.B., and Ahuja, N. (2017). Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0179501"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1158\/1078-0432.CCR-17-1958","article-title":"Epigenetic reprogramming strategies to reverse global loss of 5-hydroxymethylcytosine, a prognostic factor for poor survival in high-grade serous ovarian cancer","volume":"24","author":"Tucker","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-18-0204","article-title":"An effective epigenetic-PARP inhibitor combination therapy for breast and ovarian cancers independent of BRCA mutations","volume":"24","author":"Pulliam","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/cncr.25701","article-title":"Phase Ib-IIa study to reverse platinum resistance by the use of a hypomethylating agent azacitidine in platinum-resistant or refractory epithelial ovarian cancer","volume":"117","author":"Fu","year":"2010","journal-title":"Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1002\/cncr.29082","article-title":"Intermediate clinical endpoints: A bridge between progression-free survival and overall survival in ovarian cancer trials","volume":"121","author":"Matulonis","year":"2015","journal-title":"Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.semcancer.2015.02.006","article-title":"Sustained proliferation in cancer: Mechanisms and novel therapeutic targets","volume":"35","author":"Feitelson","year":"2015","journal-title":"Semin. Cancer Biol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1368321","DOI":"10.1080\/16546628.2017.1368321","article-title":"Thiol-reducing agents prevent sulforaphane-induced growth inhibition in ovarian cancer cells","volume":"61","author":"Kim","year":"2017","journal-title":"Food Nutr. Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e00753","DOI":"10.1016\/j.heliyon.2018.e00753","article-title":"Food-derived polyphenols inhibit the growth of ovarian cancer cells irrespective of their ability to induce antioxidant responses","volume":"4","author":"Kwon","year":"2018","journal-title":"Heliyon"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"21126","DOI":"10.1002\/jcp.28715","article-title":"Modulation of Myb-induced NF-kB-STAT3 signaling and resulting cisplatin resistance in ovarian cancer by dietary factors","volume":"234","author":"Tian","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e16308","DOI":"10.7717\/peerj.16308","article-title":"Sulforaphene suppressed cell proliferation and promoted apoptosis of COV362 cells in endometrioid ovarian cancer","volume":"11","author":"Yu","year":"2023","journal-title":"PeerJ"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.yexcr.2012.12.026","article-title":"Epigallocatechin gallate and sulforaphane combination treatment induce apoptosis in paclitaxel-resistant ovarian cancer cells through hTERT and Bcl-2 down-regulation","volume":"319","author":"Chen","year":"2013","journal-title":"Exp. Cell Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"61403","DOI":"10.18632\/oncotarget.8968","article-title":"Sulforaphane-induced apoptosis involves the type 1 IP3 receptor","volume":"7","author":"Hudecova","year":"2016","journal-title":"Oncotarget"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.canlet.2017.09.050","article-title":"The use of natural compounds for the targeting and chemoprevention of ovarian cancer","volume":"411","author":"Pistollato","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"112061","DOI":"10.1016\/j.yexcr.2020.112061","article-title":"Sulforaphane enhances the cisplatin sensitivity through regulating DNA repair and accumulation of intracellular cisplatin in ovarian cancer cells","volume":"393","author":"Gong","year":"2020","journal-title":"Exp. Cell Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.toxlet.2014.08.018","article-title":"Modulation of cisplatin sensitivity in human ovarian carcinoma A2780 and SKOV3 cell lines by sulforaphane","volume":"230","author":"Hunakova","year":"2014","journal-title":"Toxicol. Lett."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Kiselev, V.I., Ashrafyan, L.A., Muyzhnek, E.L., Gerfanova, E.V., Antonova, I.B., Aleshikova, O.I., and Sarkar, F.H. (2018). A new promising way of maintenance therapy in advanced ovarian cancer: A comparative clinical study. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4792-9"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Kelly, R., Aviles, D., Krisulevicz, C., Hunter, K., Krill, L., Warshal, D., and Ostrovsky, O. (2023). The effects of natural epigenetic therapies in 3D ovarian cancer and patient-derived tumor explants: New avenues in regulating the cancer secretome. Biomolecules, 13.","DOI":"10.3390\/biom13071066"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/bjc.2011.546","article-title":"Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment","volume":"106","author":"Agadjanian","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ygyno.2008.05.001","article-title":"Synergistic action of dietary phyto-antioxidants on survival and proliferation of ovarian cancer cells","volume":"110","author":"Raj","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.2174\/1389450117666160401124842","article-title":"Phytometabolites targeting the Warburg effect in cancer cells: A mechanistic review","volume":"18","author":"Hasanpourghadi","year":"2017","journal-title":"Curr. Drug Targets"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cbi.2005.12.009","article-title":"Free radicals, metals and antioxidants in oxidative stress-induced cancer","volume":"160","author":"Valko","year":"2006","journal-title":"Chem.-Biol. Interact."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.etap.2018.09.012","article-title":"Safrole induced cytotoxicity, DNA damage, and apoptosis in macrophages via reactive oxygen species generation and Akt phosphorylation","volume":"64","author":"Chien","year":"2018","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.21873\/anticanres.12908","article-title":"Evaluation of therapeutic potential of phenoxodiol, a novel isoflavone analog, in renal cancer cells","volume":"38","author":"Isono","year":"2018","journal-title":"Anticancer. Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.lfs.2018.08.025","article-title":"Luteolin induces caspase-dependent apoptosis via inhibiting the AKT\/osteopontin pathway in human hepatocellular carcinoma SK-Hep-1 cells","volume":"209","author":"Im","year":"2018","journal-title":"Life Sci."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.etap.2017.06.004","article-title":"Icariin exerts inhibitory effects on the growth and metastasis of KYSE70 human esophageal carcinoma cells via PI3K\/AKT and STAT3 pathways","volume":"54","author":"Gu","year":"2017","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.biopha.2017.04.001","article-title":"Baicalein increases cisplatin sensitivity of A549 lung adenocarcinoma cells via PI3K\/Akt\/NF-\u03baB pathway","volume":"90","author":"Yu","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.bbrc.2018.01.003","article-title":"Irigenin sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells","volume":"496","author":"Xu","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Jaudan, A., Sharma, S., Malek, S.N.A., and Dixit, A. (2018). Induction of apoptosis by pinostrobin in human cervical cancer cells: Possible mechanism of action. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0191523"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.fct.2017.12.018","article-title":"Apigenin promotes TRAIL-mediated apoptosis regardless of ROS generation","volume":"111","author":"Kang","year":"2018","journal-title":"Food Chem. Toxicol."},{"key":"ref_119","first-page":"5096","article-title":"Kaempferol sensitizes human ovarian cancer cells-OVCAR-3 and SKOV-3 to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis via JNK\/ERK-CHOP pathway and up-regulation of death receptors 4 and 5","volume":"23","author":"Zhao","year":"2017","journal-title":"Med. Sci. Monit. Int. Med. J. Exp. Clin. Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3109\/07357900903287006","article-title":"Curcumin inhibits constitutive STAT3 phosphorylation in human pancreatic cancer cell lines and downregulation of survivin\/BIRC5 gene expression","volume":"28","author":"Glienke","year":"2009","journal-title":"Cancer Investig."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.3892\/ol.2015.2988","article-title":"Resveratrol inhibits the hedgehog signaling pathway and epithelial-mesenchymal transition and suppresses gastric cancer invasion and metastasis","volume":"9","author":"Gao","year":"2015","journal-title":"Oncol. Lett."},{"key":"ref_122","first-page":"2519","article-title":"Epigallocatechin-3-gallate, a natural polyphenol, inhibits cell proliferation and induces apoptosis in human ovarian cancer cells","volume":"30","author":"Rao","year":"2010","journal-title":"Anticancer. Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2174\/156652412798889063","article-title":"Anti-cancer activities of tea epigallocatechin-3-gallate in breast cancer patients under radiotherapy","volume":"12","author":"Zhang","year":"2012","journal-title":"Curr. Mol. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.3892\/or.2013.2743","article-title":"Mechanism of the inhibition of the STAT3 signaling pathway by EGCG","volume":"30","author":"Wang","year":"2013","journal-title":"Oncol. Rep."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Tang, S.-N., Fu, J., Shankar, S., and Srivastava, R.K. (2012). EGCG enhances the therapeutic potential of gemcitabine and CP690550 by inhibiting STAT3 signaling pathway in human pancreatic cancer. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0031067"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1055\/s-0031-1286306","article-title":"Formononetin induces cell cycle arrest of human breast cancer cells via IGF1\/PI3K\/Akt pathways in vitro and in vivo","volume":"43","author":"Chen","year":"2011","journal-title":"Horm. Metab. Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1248\/bpb.b18-00002","article-title":"Synergistic anticancer effects of formononetin and temozolomide on glioma C6 cells","volume":"41","author":"Zhang","year":"2018","journal-title":"Biol. Pharm. Bull."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1007\/s10637-019-00767-7","article-title":"Discovery and anticancer evaluation of a formononetin derivative against gastric cancer SGC7901 cells","volume":"37","author":"Yao","year":"2019","journal-title":"Investig. New Drugs"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1111\/jphp.13176","article-title":"Ethoxy mansonone G as an anticancer agent in estrogen receptor-positive and endocrine-resistant breast cancer","volume":"71","author":"Chonsut","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: The metabolic requirements of cell proliferation","volume":"324","author":"Cantley","year":"2009","journal-title":"Science"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e1600200","DOI":"10.1126\/sciadv.1600200","article-title":"Fundamentals of cancer metabolism","volume":"2","author":"DeBerardinis","year":"2016","journal-title":"Sci. Adv."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.canlet.2012.03.031","article-title":"Graviola: A novel promising natural-derived drug that inhibits tumorigenicity and metastasis of pancreatic cancer cells in vitro and in vivo through altering cell metabolism","volume":"323","author":"Torres","year":"2012","journal-title":"Cancer Lett."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"23135","DOI":"10.1038\/srep23135","article-title":"Graviola inhibits hypoxia-induced NADPH oxidase activity in prostate cancer cells reducing their proliferation and clonogenicity","volume":"6","author":"Deep","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jep.2014.08.011","article-title":"Annona muricata leaves induce G1 cell cycle arrest and apoptosis through mitochondria-mediated pathway in human HCT-116 and HT-29 colon cancer cells","volume":"156","author":"Moghadamtousi","year":"2014","journal-title":"J. Ethnopharmacol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1826170","DOI":"10.1155\/2018\/1826170","article-title":"Anticancer properties of graviola (Annona muricata): A comprehensive mechanistic review","volume":"2018","author":"Rady","year":"2018","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41389-023-00460-8","article-title":"Involvement of the pro-oncogenic enzyme fatty acid synthase in the hallmarks of cancer: A promising target in anti-cancer therapies","volume":"12","author":"Vanauberg","year":"2023","journal-title":"Oncogenesis"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"5934","DOI":"10.1158\/0008-5472.CAN-05-3197","article-title":"Mechanism of apoptosis induced by the inhibition of fatty acid synthase in breast cancer cells","volume":"66","author":"Bandyopadhyay","year":"2006","journal-title":"Cancer Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"10247","DOI":"10.1007\/s13277-016-4912-6","article-title":"Kaempferol inhibits cell proliferation and glycolysis in esophagus squamous cell carcinoma via targeting EGFR signaling pathway","volume":"37","author":"Yao","year":"2016","journal-title":"Tumor Biol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"202","DOI":"10.4161\/auto.6.2.10971","article-title":"Carcinoma cells activate AMP-activated protein kinase-dependent autophagy as survival response to kaempferol-mediated energetic impairment","volume":"6","author":"Filomeni","year":"2010","journal-title":"Autophagy"},{"key":"ref_140","first-page":"1047","article-title":"Resveratrol Downregulates Acetyl-CoA Carboxylase \u03b1 and Fatty Acid Synthase by AMPK-mediated Downregulation of mTOR in Breast Cancer Cells","volume":"17","author":"Park","year":"2008","journal-title":"Food Sci. Biotechnol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"7904","DOI":"10.1080\/21655979.2022.2052673","article-title":"Shikonin induces apoptosis and autophagy via downregulation of pyrroline-5-carboxylate reductase1 in hepatocellular carcinoma cells","volume":"13","author":"Zhang","year":"2022","journal-title":"Bioengineered"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1126\/science.aav2588","article-title":"Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion","volume":"366","author":"Leone","year":"2019","journal-title":"Science"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.canlet.2016.06.023","article-title":"Apigenin inhibits the inducible expression of programmed death ligand 1 by human and mouse mammary carcinoma cells","volume":"380","author":"Coombs","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s13046-018-0929-6","article-title":"Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects","volume":"37","author":"Xu","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Nelson, N., Szekeres, K., Iclozan, C., Rivera, I.O., McGill, A., Johnson, G., Nwogu, O., and Ghansah, T. (2017). Apigenin: Selective CK2 inhibitor increases Ikaros expression and improves T cell homeostasis and function in murine pancreatic cancer. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0170197"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/j.apsb.2020.06.014","article-title":"Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5","volume":"10","author":"Liu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Rawangkan, A., Wongsirisin, P., Namiki, K., Iida, K., Kobayashi, Y., Shimizu, Y., Fujiki, H., and Suganuma, M. (2018). Green tea catechin is an alternative immune checkpoint inhibitor that inhibits PD-L1 expression and lung tumor growth. Molecules, 23.","DOI":"10.3390\/molecules23082071"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.4049\/jimmunol.1501158","article-title":"Dectin-1 activation by a natural product \u03b2-glucan converts immunosuppressive macrophages into an M1-like phenotype","volume":"195","author":"Liu","year":"2015","journal-title":"J. Immunol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"e1387347","DOI":"10.1080\/2162402X.2017.1387347","article-title":"Systemic administration of \u03b2-glucan of 200 kDa modulates melanoma microenvironment and suppresses metastatic cancer","volume":"7","author":"Zhang","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s12013-015-0513-z","article-title":"Modification of antitumor immunity and tumor microenvironment by resveratrol in mouse renal tumor model","volume":"72","author":"Chen","year":"2015","journal-title":"Cell Biochem. Biophys."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.4049\/jimmunol.1300606","article-title":"Inhibition of breast cancer metastasis by resveratrol-mediated inactivation of tumor-evoked regulatory B cells","volume":"191","author":"Bodogai","year":"2013","journal-title":"J. Immunol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.intimp.2007.05.008","article-title":"Resveratrol induces apoptosis, influences IL-6 and exerts immunomodulatory effect on mouse lymphocytic leukemia both in vitro and in vivo","volume":"7","author":"Li","year":"2007","journal-title":"Int. Immunopharmacol."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Kang, D.Y., Sp, N., Jo, E.S., Rugamba, A., Hong, D.Y., Lee, H.G., Yoo, J.-S., Liu, Q., Jang, K.-J., and Yang, Y.M. (2020). The inhibitory mechanisms of tumor PD-L1 expression by natural bioactive gallic acid in non-small-cell lung cancer (NSCLC) cells. Cancers, 12.","DOI":"10.3390\/cancers12030727"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"11560","DOI":"10.1038\/s41598-019-47903-0","article-title":"Anthocyanins, delphinidin-3-O-glucoside and cyanidin-3-O-glucoside, inhibit immune checkpoints in human colorectal cancer cells in vitro and in silico","volume":"9","author":"Mazewski","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.archoralbio.2018.04.015","article-title":"Curcumin enhances anti-tumor immune response in tongue squamous cell carcinoma","volume":"92","author":"Liao","year":"2018","journal-title":"Arch. Oral Biol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.intimp.2016.07.035","article-title":"Inhibition of curcumin on myeloid-derived suppressor cells is requisite for controlling lung cancer","volume":"39","author":"Liu","year":"2016","journal-title":"Int. Immunopharmacol."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Paudel, S., Mishra, N., and Agarwal, R. (2023). Phytochemicals as immunomodulatory molecules in cancer therapeutics. Pharmaceuticals, 16.","DOI":"10.3390\/ph16121652"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1080\/08923970500242244","article-title":"Immunomodulatory effects of curcumin","volume":"27","author":"Yadav","year":"2005","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.bbamcr.2007.04.015","article-title":"Curcumin reverses breast tumor exosomes mediated immune suppression of NK cell tumor cytotoxicity","volume":"1773","author":"Zhang","year":"2007","journal-title":"Biochim. Biophys. Acta (BBA)-Mol. Cell Res."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.3390\/molecules20023020","article-title":"Curcumin and omega-3 fatty acids enhance NK cell-induced apoptosis of pancreatic cancer cells but curcumin inhibits interferon-\u03b3 production: Benefits of omega-3 with curcumin against cancer","volume":"20","author":"Fiala","year":"2015","journal-title":"Molecules"},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Paul, S., and Sa, G. (2021). Curcumin as an adjuvant to cancer immunotherapy. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.675923"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13048-018-0412-1","article-title":"S-allylcysteine suppresses ovarian cancer cell proliferation by DNA methylation through DNMT1","volume":"11","author":"Xu","year":"2018","journal-title":"J. Ovarian Res."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"100074","DOI":"10.1016\/j.prmcm.2022.100074","article-title":"Sesquiterpene lactones modulated DNA methylation through inhibition of DNMTs in ovarian cancer cells","volume":"3","author":"Fadayomi","year":"2022","journal-title":"Pharmacol. Res.-Mod. Chin. Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/mc.23856","article-title":"Wogonin Inhibits Ovarian Cancer by Activating the AMPK-TET2-5hmC Axis","volume":"64","author":"Yang","year":"2025","journal-title":"Mol. Carcinog."},{"key":"ref_165","first-page":"827","article-title":"Curcumin induces re-expression of BRCA1 and suppression of \u03b3 synuclein by modulating DNA promoter methylation in breast cancer cell lines","volume":"43","author":"Shinwari","year":"2020","journal-title":"Oncol. Rep."},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Hassan, F.-U., Rehman, M.S.-U., Khan, M.S., Ali, M.A., Javed, A., Nawaz, A., and Yang, C. (2019). Curcumin as an alternative epigenetic modulator: Mechanism of action and potential effects. Front. Genet., 10.","DOI":"10.3389\/fgene.2019.00514"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"114350","DOI":"10.1016\/j.biopha.2023.114350","article-title":"Luteolin directly binds to KDM4C and attenuates ovarian cancer stemness via epigenetic suppression of PPP2CA\/YAP axis","volume":"160","author":"Li","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/biof.1544","article-title":"Resveratrol modulates epigenetic regulators of promoter histone methylation and acetylation that restores BRCA1, p53, p21CIP1 in human breast cancer cell lines","volume":"45","author":"Chatterjee","year":"2019","journal-title":"BioFactors"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/mc.22582","article-title":"Resveratrol inhibits IL-6-induced ovarian cancer cell migration through epigenetic up-regulation of autophagy","volume":"56","author":"Ferraresi","year":"2017","journal-title":"Mol. Carcinog."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Kciuk, M., Alam, M., Ali, N., Rashid, S., G\u0142owacka, P., Sundaraj, R., Celik, I., Yahya, E.B., Dubey, A., and Zerroug, E. (2023). Epigallocatechin-3-gallate therapeutic potential in cancer: Mechanism of action and clinical implications. Molecules, 28.","DOI":"10.3390\/molecules28135246"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00280-017-3238-4","article-title":"Curcumin suppresses cisplatin resistance development partly via modulating extracellular vesicle-mediated transfer of MEG3 and miR-214 in ovarian cancer","volume":"79","author":"Zhang","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"122224","DOI":"10.1016\/j.lfs.2023.122224","article-title":"Curcumin modulates cell type-specific miRNA networks to induce cytotoxicity in ovarian cancer cells","volume":"334","author":"Ravindran","year":"2023","journal-title":"Life Sci."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"5351","DOI":"10.21873\/anticanres.17362","article-title":"Effects of curcumin and its analogue desmethoxycurcumin on miR-133b and its target gene GSTP-1 in cisplatin-resistant ovarian cancer cells","volume":"44","author":"Seyhan","year":"2024","journal-title":"Anticancer. Res."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.3892\/etm.2017.4889","article-title":"Ginsenoside Rb1 inhibits hypoxia-induced epithelial-mesenchymal transition in ovarian cancer cells by regulating microRNA-25","volume":"14","author":"Liu","year":"2017","journal-title":"Exp. Ther. Med."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1159\/000495552","article-title":"Ginsenoside 20 (S)-Rg3 prevents PKM2-targeting miR-324-5p from H19 sponging to antagonize the Warburg effect in ovarian cancer cells","volume":"51","author":"Zheng","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.3892\/mmr.2015.3679","article-title":"Quercetin induces the apoptosis of human ovarian carcinoma cells by upregulating the expression of microRNA-145","volume":"12","author":"Zhou","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.2174\/1381612826666201019102207","article-title":"Quercetin and MicroRNA interplay in apoptosis regulation in ovarian cancer","volume":"27","author":"Khan","year":"2021","journal-title":"Curr. Pharm. Des."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/abbs\/gmt075","article-title":"Berberine sensitizes ovarian cancer cells to cisplatin through miR-21\/PDCD4 axis","volume":"45","author":"Liu","year":"2013","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"ref_179","first-page":"1126","article-title":"Oncogenic MicroRNA-27a is a target for genistein in ovarian cancer cells","volume":"13","author":"Xu","year":"2013","journal-title":"Anti-Cancer Agents Med. Chem. (Former. Curr. Med. Chem.-Anti-Cancer Agents)"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"BSR20193396","DOI":"10.1042\/BSR20193396","article-title":"Astragalus polysaccharides inhibit ovarian cancer cell growth via microRNA-27a\/FBXW7 signaling pathway","volume":"40","author":"Guo","year":"2020","journal-title":"Biosci. Rep."},{"key":"ref_181","first-page":"2063","article-title":"Emodin inhibits TGF-\u03b22 by activating the FOXD3\/miR-199a axis in ovarian cancer cells in vitro","volume":"39","author":"Song","year":"2018","journal-title":"Oncol. Rep."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.3892\/or.2015.3891","article-title":"Icariin regulates the proliferation and apoptosis of human ovarian cancer cells through microRNA-21 by targeting PTEN, RECK and Bcl-2","volume":"33","author":"Li","year":"2015","journal-title":"Oncol. Rep."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13027-019-0247-4","article-title":"Resveratrol induces immunogenic cell death of human and murine ovarian carcinoma cells","volume":"14","author":"Zhang","year":"2019","journal-title":"Infect. Agents Cancer"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/cncr.29793","article-title":"Resveratrol inhibits ovarian tumor growth in an in vivo mouse model","volume":"122","author":"Tan","year":"2016","journal-title":"Cancer"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"7449","DOI":"10.1158\/0008-5472.CAN-09-1266","article-title":"Resveratrol suppresses growth of human ovarian cancer cells in culture and in a murine xenograft model: Eukaryotic elongation factor 1A2 as a potential target","volume":"69","author":"Lee","year":"2009","journal-title":"Cancer Res."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3233\/CBM-170483","article-title":"Correlation of ARHI upregulation with growth suppression and STAT3 inactivation in resveratrol-treated ovarian cancer cells","volume":"21","author":"Zhong","year":"2018","journal-title":"Cancer Biomark."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.nano.2019.03.011","article-title":"Chemosensitization and mitigation of Adriamycin-induced cardiotoxicity using combinational polymeric micelles for co-delivery of quercetin\/resveratrol and resveratrol\/curcumin in ovarian cancer","volume":"19","author":"Shah","year":"2019","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_188","first-page":"1885","article-title":"PTEN\/AKT\/mTOR signaling mediates anticancer effects of epigallocatechin-3-gallate in ovarian cancer","volume":"43","author":"Qin","year":"2020","journal-title":"Oncol. Rep."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s11626-023-00830-x","article-title":"Epigallocatechin gallate inhibits ovarian cancer cell growth and induces cell apoptosis via activation of FOXO3A","volume":"59","author":"Zhang","year":"2023","journal-title":"Vitr. Cell. Dev. Biol.-Anim."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1158\/1078-0432.CCR-06-3072","article-title":"Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-\u03baB pathway","volume":"13","author":"Lin","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"9703","DOI":"10.2147\/IJN.S274083","article-title":"Co-delivery of docetaxel and curcumin via nanomicelles for enhancing anti-ovarian cancer treatment","volume":"15","author":"Hu","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Winardi, D., Chu, P.-Y., Chen, G.-Y., Wang, K., Hsu, W.-Y., Hsieh, C.-L., Chen, Y.-H., Wu, Y.-C., and Yang, J.-C. (2022). Novel Aurora A kinase inhibitor fangchinoline enhances cisplatin\u2013DNA adducts and cisplatin therapeutic efficacy in OVCAR-3 ovarian cancer cells-derived xenograft model. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031868"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1517\/14656560902837980","article-title":"Phenoxodiol: Pharmacology and clinical experience in cancer monotherapy and in combination with chemotherapeutic drugs","volume":"10","author":"Silasi","year":"2009","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/IGC.0b013e3182126f05","article-title":"Phase II evaluation of phenoxodiol in combination with cisplatin or paclitaxel in women with platinum\/taxane-refractory\/resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers","volume":"21","author":"Kelly","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1365-2613.2002.00211.x","article-title":"The biology of the combretastatins as tumour vascular targeting agents","volume":"83","author":"Tozer","year":"2002","journal-title":"Int. J. Exp. Pathol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1093\/annonc\/mdq708","article-title":"Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer","volume":"22","author":"Zweifel","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_197","unstructured":"Ueland, F.R. (2025, December 29). Phase 1 Clinical Trial. Dose Escalation of ArtemiCoffee, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04805333#study-overview."}],"container-title":["Epigenomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4655\/10\/2\/23\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T08:42:19Z","timestamp":1775032939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4655\/10\/2\/23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":197,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["epigenomes10020023"],"URL":"https:\/\/doi.org\/10.3390\/epigenomes10020023","relation":{},"ISSN":["2075-4655"],"issn-type":[{"value":"2075-4655","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}